Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elephantopus scaber is a traditional Asian medicinal plant belonging to the Asteraceae family, widely used in Southeast Asia and China for its heat-clearing, detoxifying, and anti-inflammatory properties. Its therapeutic efficacy is primarily attributed to sesquiterpene lactones, most notably deoxyelephantopin (DET) and isodeoxyelephantopin (IDET). Preclinical research has demonstrated a broad pharmacological spectrum, including potent anticancer activity against various malignancies (such as triple-negative breast cancer, glioblastoma, and oral cancer), anti-inflammatory effects in models of ulcerative colitis and atopic dermatitis, and neuroprotective potential in neurodegenerative disease models. Mechanistically, extracts and isolated compounds modulate key signaling pathways including NF-κB, PI3K/Akt/mTOR, STAT3, and the NLRP3 inflammasome. While it shows promise as a source of drug leads, current evidence is limited to in vitro and animal studies, with no clinical data yet available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on elephantopus scaber.